trending Market Intelligence /marketintelligence/en/news-insights/trending/Ed7bUTd8t3RPK2LJQ6ECTQ2 content esgSubNav
In This List

Illumina wins patent infringement suits against Premaitha, Ariosa in UK

Blog

Insight Weekly: Layoffs swell; energy efficiency PE deals defy downturn; 2023 global risk themes

Blog

Insight Weekly: Energy crisis cripples Europe; i-bank incomes rise; US holiday sales outlook

Blog

Japan M&A By the Numbers: Q3 2022

Blog

Insight Weekly: Reviving nuclear power; 2023 outlook for US financials; PE funds fuel EV sector


Illumina wins patent infringement suits against Premaitha, Ariosa in UK

Illumina Inc. said it won a favorable ruling in the patent infringement suits filed against Premaitha Health PLC and Ariosa Diagnostics Inc. in the U.K.

The High Court of Justice, Chancery Division, Patents Court in the U.K ruled that Premaitha's IONA test infringed patents related to the use of sequencing in noninvasive prenatal testing.

The court added that the gender-testing component in the IONA test and Ariosa's Harmony test infringed on another patent.

These patents are licensed by Illumina or its wholly owned subsidiary Verinata Health Inc.

Illumina, which earlier filed multiple lawsuits against Premaitha, said it intends to seek all available remedies, including damages, injunctive relief and attorney fees.

Ariosa Diagnostics Inc. is an indirect subsidiary of Swiss drugmaker Roche Holding AG.